Destiny Pharma’s (DEST) “House Stock” Rating Reaffirmed at Shore Capital

Shore Capital restated their house stock rating on shares of Destiny Pharma (LON:DESTGet Rating) in a research note released on Wednesday morning, Marketbeat reports.

Destiny Pharma Price Performance

Shares of LON DEST opened at GBX 32.35 ($0.38) on Wednesday. The company has a market cap of £23.71 million and a PE ratio of -3.65. Destiny Pharma has a 12 month low of GBX 31.30 ($0.37) and a 12 month high of GBX 118 ($1.40). The company has a 50-day simple moving average of GBX 35.70 and a 200-day simple moving average of GBX 39.35.

Destiny Pharma Company Profile

(Get Rating)

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria.

Read More

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.